Search results for "Transaminase"

showing 10 items of 145 documents

Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia

2019

Aim Currently there are some large-scale studies of elevated total vitamin B12 in relation to diseases and their prognosis. Aim of this retrospective study was to determine association of increased B12 as an additional diagnostic marker of oncohematological diseases by a statistical analysis of clinical data of 79,524 patients. Materials and methods Overall Latvian population representative data on B12 testing in 79,524 patients were obtained from laboratory database. The following exclusion criteria were applied: fluctuating B12 results within a three-month period, elevated (> 100 U/L) alanine transaminase or aspartate transaminase, hepatitis (HAV, HBV, and HCV) infection, reduced glomerul…

HepatitisCancer Researchmedicine.medical_specialtyeducation.field_of_studybiologybusiness.industryPopulationAspartate transaminaseRetrospective cohort studyOdds ratiomedicine.diseaseGastroenterology03 medical and health sciences0302 clinical medicineOncologyAlanine transaminase030220 oncology & carcinogenesisInternal medicineCohortbiology.proteinMedicinebusinesseducationCohort studyExperimental Oncology
researchProduct

Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

2012

Abstract Abstract 4956 Introduction. Patients with Myelodysplastic Syndrome (MDS) are susceptible to developing iron overload as a response to the red blood cell (RBC) transfusions and ineffective hematopoiesis. This iron overload (IOL) is characterized by an increase in oxygen-reactive species accompanied by a decrease in antioxidants, and results in hepatic, cardiac and endocrine disorders, as well as an increased risk of infection. Ineffective hematopoiesis promotes iron absorption at intestinal level. This process is enhanced by the presence of mutations in the hereditary hemochromatosis gene (HFE). This study aims to define the features that accompany patients with iron overload, compa…

Ineffective Hematopoiesismedicine.medical_specialtyPathologyLiver Iron Concentrationeducation.field_of_studybiologybusiness.industryImmunologyPopulationCell BiologyHematologyBiochemistryGastroenterologyRed blood cellmedicine.anatomical_structureAlanine transaminaseRefractory sideroblastic anemiaInternal medicineHereditary hemochromatosismedicinebiology.proteinChelation therapybusinesseducation
researchProduct

HSP60 and CpG-DNA-oligonucleotides differentially regulate LPS-tolerance of hepatic Kupffer cells

2004

Background/aims: Hepatic Kupffer cells (KC) are major regulators of the immune response to gut-derived bacterial products; uncontrolled activation of KC by bacterial components is of pathogenic relevance in alcoholic hepatitis and septic shock. Methods: We examined the role of bacterial lipopolysaccharide (LPS), bacterial and autologous HSP60 and bacterial DNA, which are recognized by innate Toll-like receptors, during activation of murine KC. Results: In cultivated KC, autologous HSP60 induced a state of LPS-hyporesponsiveness; bacterial DNA did not mitigate the response to subsequent LPS-challenge in vitro; in contrast, pre-treatment of mice with bacterial DNA even significantly increased…

LipopolysaccharidesMaleLipopolysaccharideKupffer CellsImmunologyGene ExpressionGalactosamineReceptors Cell SurfaceCell LineMicrobiologyMicechemistry.chemical_compoundImmune systemImmunityHeat shock proteinAnimalsImmunology and AllergyInterleukin 6Cells CulturedbiologyInterleukin-6Reverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaAlanine TransaminaseChaperonin 60Macrophage ActivationToll-Like Receptor 9DNA-Binding ProteinsToll-Like Receptor 4LiverOligodeoxyribonucleotideschemistryToll-Like Receptor 9Immunologybiology.proteinFemaleHSP60Tumor necrosis factor alphaLiver FailureImmunology Letters
researchProduct

Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver

2012

Background: The prevalence of hepatitis C virus infection increases with advancing age, but elderly hepatitis C virus patients remain an understudied population. Aim: To define the virological, epidemiological and clinical profiles of Italian outpatients aged 65 years and over infected by hepatitis C virus. Methods: We evaluated 1544 anti-hepatitis C virus positive patients aged >=65 years referred to 34 Italian outpatient specialty clinics over a two-year period. Results: The study population included 1134 (73%) early elderly (65-74 years) and 410 (27%) late elderly patients (>=75 years). Late elderly subjects were less likely to have their virus genotyped, their viral load assessed or a h…

Liver CirrhosisMaleAGED PATIENTS; EPIDEMIOLOGY; HCV INFECTION; LIVER DISEASES; ANTI-VIRAL TREATMENTEpidemiologyCross-sectional studyHepacivirusLIVER DISEASESmedicine.disease_causeLiver disease80 and overPrevalenceEPIDEMIOLOGYChronicAged patientsAged 80 and overeducation.field_of_studyhepatitis c elderly italyAge FactorsHCV INFECTIONGastroenterologyliver diseases; hepatitis c elderly italy; hcv infection; epidemiology; aged patientsAlanine TransaminaseHepatitis CViral LoadAGED PATIENTSHepatitis CHCV infectionItalyHCVAged patients; Epidemiology; HCV infection; Liver diseasesPopulation studyFemaleViral loadmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusPopulationgeriatricAntiviral AgentsInternal medicinemedicineHumanseducationSettore MED/42 - IGIENE GENERALE E APPLICATALiver diseasesAgedHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C ChronicHepatitis C AntibodiesHepatologymedicine.diseaseSurgeryCross-Sectional StudiesAged patients; Epidemiology; HCV infection; Liver diseases; Age Factors; Aged; Aged 80 and over; Alanine Transaminase; Antiviral Agents; Cross-Sectional Studies; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Male; Prevalence; Viral Load; Gastroenterology; HepatologyANTI-VIRAL TREATMENTbusiness
researchProduct

Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta.

2001

Although many patients with chronic viral hepatitis C infection suffer from progressive liver disease, the rate of fibrosis progression is highly variable and some patients do not show any measurable progression. However, our ability to predict which patients progress is very limited. Since transforming growth factor-beta (TGF-beta) is a key mediator of liver fibrogenesis, we assessed the predictive role of TGF-beta for fibrogenesis in chronic hepatitis C. We studied 39 patients with chronic hepatitis C in whom two liver biopsies were taken at least 12 months apart, and who did not receive therapy during this period. TGF-beta was measured by bioassay and by ELISA in serum samples taken at t…

Liver CirrhosisMalePathologymedicine.medical_specialtyCirrhosisAntiviral AgentsSeverity of Illness IndexFibrosisPredictive Value of TestsTransforming Growth Factor betaVirologyBiopsymedicineHumansHepatologymedicine.diagnostic_testbusiness.industryAlanine TransaminaseHepatitis CHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseInfectious DiseasesLiver biopsyPredictive value of testsChronic DiseaseDisease ProgressionFemalebusinessViral loadProgressive diseaseBiomarkersProcollagenJournal of viral hepatitis
researchProduct

Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients with No…

2019

Some evidence suggests an interference of obesity and alanine aminotransferase (ALT) levels on the diagnostic accuracy for advanced fibrosis of noninvasive tools such as liver stiffness measurement (LSM) by FibroScan, Fibrosis-4 (FIB-4), and nonalcoholic fatty liver disease fibrosis score (NFS). We assessed whether the diagnostic accuracy of LSM, Fibrosis-4 (FIB-4), and NFS and strategies based on the combination of these tools is affected by obesity and/or ALT levels.METHODS:We analyzed data from 968 patients with a histological diagnosis of nonalcoholic fatty liver disease. FIB-4, NFS, and LSM by FibroScan were measured.RESULTS:LSM was better than both FIB-4 and NFS for staging F3-F4 fibr…

Liver CirrhosisMalemedicine.medical_specialtyBiopsySeverity of Illness IndexGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseasePredictive Value of TestsFibrosisInternal medicineSeverity of illnessBiopsyNonalcoholic fatty liver diseasemedicineHumansAspartate AminotransferasesObesityNASH FIBROSISHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologyAlanine TransaminaseMiddle Agedmedicine.diseaseLiverROC Curve030220 oncology & carcinogenesisPredictive value of testsElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologySteatosisHepatic fibrosisbusinessBiomarkers
researchProduct

Efficacy of an escalating dose regimen of pegylated interferon ?-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation

2007

We evaluated the safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2a (PEG-IFN(alpha-2a)) and ribavirin in the early phase of recurrent hepatitis C after orthotopic liver transplantation (OLT). In this prospective study, 26 patients transplanted for hepatitis C virus cirrhosis with recurrent hepatitis C were treated 3.4 +/- 3.6 months after OLT and compared with an untreated historical control. PEG-IFN(alpha-2a) was initiated as monotherapy, following stepwise dose escalation up to 180 mug/week and the addition of ribavirin up to 1200 mg/day or maximally tolerated doses for 48 weeks. In the intent-to-treat analysis, 38% showed an early virological response (EVR…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene GlycolsCohort Studieschemistry.chemical_compoundPostoperative ComplicationsPegylated interferonRecurrenceInternal medicineRibavirinmedicineHumansAdverse effectAgedTransplantationbusiness.industryRibavirinInterferon-alphaAlanine TransaminaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CRecombinant ProteinsLiver TransplantationRegimenTreatment OutcomechemistryImmunologyRNA ViralFemalebusinessmedicine.drugTransplant International
researchProduct

An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers

2018

Background & Aims Interventions aimed at lifestyle changes are pivotal for the treatment of non-alcoholic fatty liver disease (NAFLD), and web-based programs might help remove barriers in both patients and therapists. Methods In the period 2010–15, 716 consecutive NAFLD cases (mean age, 52; type 2 diabetes, 33%) were treated in our Department with structured programs. The usual protocol included motivational interviewing and a group-based intervention (GBI), chaired by physicians, dietitians and psychologists (five weekly meetings, n = 438). Individuals who could not attend GBI entered a web-based intervention (WBI, n = 278) derived from GBI, with interactive games, learning tests, motivati…

Liver CirrhosisMalemedicine.medical_specialtyMotivational interviewingPsychological interventionType 2 diabetesDisease03 medical and health sciences0302 clinical medicinePatient Education as TopicWeight lossNon-alcoholic Fatty Liver DiseaseInternal medicineWeight LossmedicineHumansNAFLD progression030212 general & internal medicineExerciseLife StyleAged2. Zero hungerInternetHepatologybusiness.industryPhysical activityFatty liverLiver enzymeAlanine TransaminaseHepatologyMiddle Agedmedicine.diseaseDiet; Liver enzymes; NAFLD progression; Physical activity; HepatologyTelemedicineLiver enzymes3. Good healthDietLogistic Models030211 gastroenterology & hepatologyFemalemedicine.symptombusinessBody mass indexBiomarkers
researchProduct

Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus

2020

Abstract Background The burden of nonalcoholic fatty liver disease (NAFLD) is growing in people living with human immunodeficiency virus (HIV). NAFLD is associated with obesity; however, it can occur in normoweight (lean) patients. We aimed to investigate lean NAFLD in patients living with HIV. Methods We included patients living with HIV mono-infection from 3 prospective cohorts. NAFLD was diagnosed by transient elastography (TE) and defined as controlled attenuation parameter ≥248 dB/m, in absence of alcohol abuse. Lean NAFLD was defined when a body mass index was <25 kg/m2. Significant liver fibrosis was defined as TE ≥7.1 kPa. The presence of diabetes, hypertension, or hyperlipid…

Liver CirrhosisMicrobiology (medical)medicine.medical_specialtyTransient elastographyHIV InfectionsGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineDiabetes mellitusHyperlipidemiaNonalcoholic fatty liver diseasePrevalencemedicineHumansProspective Studies030212 general & internal medicineAgedbiologybusiness.industryHIVnutritional and metabolic diseasesLiver fibrosimedicine.diseasedigestive system diseasesInfectious DiseasesAlanine transaminaseDyslipidemiaalanine aminotransferase; controlled attenuation parameter; dyslipidemia; liver fibrosis; transient elastographyCohortControlled attenuation parameterbiology.proteinAlanine aminotransferase030211 gastroenterology & hepatologybusinessTransient elastographyBody mass indexDyslipidemia
researchProduct

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-…

2020

The impact of direct-acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA-based treatment. Patients (260) were enrolled in the German Hepatitis C-Registry (DHC-R), a national multicentre real-world cohort. Liver stiffness (LS) was assessed at baseline, end of treatment (EOT) and 24 weeks after EOT (FU24) by TE. Biochemical, virological and clinical data were obtained in parallel. In patients with SVR, there was a significant improvement of LS between baseline (median [range], 8.6 [1.7-73.5] kPa) and FU24 (7.9 […

Liver Cirrhosismedicine.medical_specialtySustained Virologic ResponseBilirubinMedizinGastroenterologyAntiviral AgentsVirusTransaminase03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrosisVirologyInternal medicineGermanymedicineHumans030212 general & internal medicineRegistriesHepatitisHepatologybusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryLiverCohortElasticity Imaging Techniques030211 gastroenterology & hepatologybusinessTransient elastographyJournal of viral hepatitisREFERENCES
researchProduct